AMF Tjanstepension AB Has $90.86 Million Stock Holdings in Boston Scientific Corporation $BSX

AMF Tjanstepension AB lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 952,950 shares of the medical equipment provider’s stock after acquiring an additional 46,538 shares during the quarter. AMF Tjanstepension AB’s holdings in Boston Scientific were worth $90,864,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of BSX. Claret Asset Management Corp boosted its holdings in Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its holdings in Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 103 shares in the last quarter. Outfitters Financial LLC boosted its holdings in Boston Scientific by 0.5% in the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after purchasing an additional 110 shares in the last quarter. Fayez Sarofim & Co boosted its holdings in Boston Scientific by 2.1% in the third quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock worth $520,000 after purchasing an additional 111 shares in the last quarter. Finally, Natural Investments LLC boosted its holdings in Boston Scientific by 2.9% during the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after acquiring an additional 112 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. BTIG Research restated a “buy” rating and set a $80.00 price target on shares of Boston Scientific in a report on Monday. The Goldman Sachs Group decreased their price target on shares of Boston Scientific from $87.00 to $84.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Finally, UBS Group decreased their price target on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.83.

Boston Scientific Stock Performance

NYSE:BSX opened at $55.86 on Tuesday. The firm has a market capitalization of $83.02 billion, a PE ratio of 23.37, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12-month low of $52.52 and a 12-month high of $109.50. The firm has a 50-day moving average price of $63.06 and a 200 day moving average price of $81.33.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific launched a $2 billion accelerated share repurchase, which should reduce share count and support earnings per share. The move signals management confidence and adds a near-term catalyst for the stock. Boston Scientific enters into $2 billion accelerated share repurchase agreement
• Positive Sentiment: The company also announced a $1.5 billion strategic investment in MiRus, taking an approximately 34% stake and gaining an exclusive option to buy MiRus’ TAVR business. Investors view this as a way for Boston Scientific to expand into the fast-growing structural heart market. Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business
• Positive Sentiment: Several analysts reiterated bullish views, including Needham and BTIG, both of which kept buy ratings and highlighted upside potential in BSX shares. Analyst rating updates
• Neutral Sentiment: Boston Scientific was also mentioned on a list of top analyst picks for the week, reflecting continued positive sentiment around the name. 3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
• Negative Sentiment: One notable offset is that Bank of America lowered its price target on BSX, even while keeping a buy rating, suggesting some caution about valuation or near-term expectations. Bank of America price target update

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.